Summary

Japan Oral Anticoagulants Market Research Report By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Disease Indication (Atrial Fibrillation, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Heart Attacks) and By Product (Novel Oral Anticoagulant, Warfarin) - Growth & Industry Forecast 2025 To 2035

Market Summary:
As per Market Research Future analysis, the Japan oral anticoagulants market size was estimated at 1547.5 USD Million in 2024. The Japan oral anticoagulants market is projected to grow from 1636.64 USD Million in 2025 to 2865.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.7% during the forecast period 2025 - 2035

Market Drivers:
Increased awareness and education regarding thrombosis and its associated risks are influencing the oral anticoagulants market in Japan. Public health campaigns and healthcare provider initiatives are effectively disseminating information about the importance of anticoagulation therapy in preventing strokes and other thromboembolic events. This heightened awareness is likely to lead to more patients seeking treatment options, thereby expanding the market. The oral anticoagulants market is benefiting from this trend, as healthcare professionals are more frequently recommending anticoagulants to at-risk populations. It is estimated that this awareness could contribute to a market growth of around 8% in the coming years, as more individuals are diagnosed and treated. Regulatory support and favorable reimbursement policies are crucial drivers for the oral anticoagulants market in Japan. The Japanese government has been actively promoting the use of anticoagulants through various healthcare policies, which facilitate access to these medications. Additionally, the inclusion of newer anticoagulants in the national health insurance system has made them more accessible to patients.

Market Segment Analysis:
The Japan Oral Anticoagulants Market exhibits growing significance within its distribution channel landscape, encompassing Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. In recent times, the role of Hospital Pharmacies has gained prominence; they are integral to the healthcare system, offering specialized pharmaceutical care to patients with complex medical needs. With their ability to provide direct access to patients admitted for cardiovascular interventions, Hospital Pharmacies are essential for ensuring proper medication management and monitoring. Retail Pharmacies, on the other hand, serve as a crucial point of access for the general public, making oral anticoagulants readily available to patients through a vast network of local drugstores, thus facilitating adherence to prescribed treatment regimens. The convenience and personalized services offered by Retail Pharmacies foster a strong patient relationship, further enhancing medication compliance.

Regional Analysis:
The oral anticoagulants market is currently experiencing notable growth, driven by an increasing prevalence of thromboembolic disorders and a rising awareness of the benefits associated with anticoagulant therapies. In Japan, the aging population is particularly susceptible to conditions such as atrial fibrillation and venous thromboembolism, which necessitate effective management through anticoagulant medications. Furthermore, advancements in drug formulations and delivery methods are enhancing patient compliance and outcomes, thereby contributing to the market's expansion. The regulatory environment in Japan is also evolving, with authorities actively promoting the use of innovative therapies to improve healthcare outcomes. In addition, the oral anticoagulants market is witnessing a shift towards more patient-centric approaches, with healthcare providers increasingly focusing on personalized medicine.

Major Players:
The following companies are key participants in the Japan Oral Anticoagulants Market, playing a crucial role in market development through technological innovation, strategic partnerships, and competitive product offerings.

ページTOPに戻る

Table of Contents

TABLE OF CONTENT
1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
EXECUTIVE SUMMARY
Market Overview
Key Findings
Market Segmentation
Competitive Landscape
Challenges and Opportunities
Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
MARKET INTRODUCTION
Definition
Scope of the study
Research Objective
Assumption
Limitations
RESEARCH METHODOLOGY
Overview
Data Mining
Secondary Research
Primary Research
Primary Interviews and Information Gathering Process
Breakdown of Primary Respondents
Forecasting Model
Market Size Estimation
Bottom-Up Approach
Top-Down Approach
Data Triangulation
Validation
3 SECTION III: QUALITATIVE ANALYSIS
MARKET DYNAMICS
Overview
Drivers
Restraints
Opportunities
MARKET FACTOR ANALYSIS
Value chain Analysis
Porter's Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of New Entrants
Threat of Substitutes
Intensity of Rivalry
COVID-19 Impact Analysis
Market Impact Analysis
Regional Impact
Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
Japan Oral Anticoagulants Market SegmentationOral Anticoagulants Distribution Channel Outlook (USD Billion, 2018-2030)Hospital PharmaciesRetail PharmaciesOnline PharmaciesOral Anticoagulants Disease Indication Outlook (USD Billion, 2018-2030)Atrial FibrillationDeep Vein Thrombosis (DVT)Pulmonary Embolism (PE)Heart AttacksOral Anticoagulants Product Outlook (USD Billion, 2018-2030)Novel Oral AnticoagulantWarfarinOral Anticoagulants SECTION V: COMPETITIVE ANALYSIS
Competitive Landscape
Overview
Competitive Analysis
Market share Analysis
Major Growth Strategy in the oral anticoagulants market
Competitive Benchmarking
Leading Players in Terms of Number of Developments in the oral anticoagulants market
Key developments and growth strategies
New Product Launch/Service Deployment
Merger & Acquisitions
Joint Ventures
Major Players Financial Matrix
Sales and Operating Income
Major Players R&D Expenditure. 2023
Company Profiles
Bristol-Myers Squibb
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Daiichi Sankyo
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Takeda Pharmaceutical Company
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Mitsubishi Tanabe Pharma Corporation
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Astellas Pharma Inc.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
On
Pharmaceutical Co. Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Chugai Pharmaceutical Co. Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Kyowa Kirin Co. Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Appendix
References
Related Reports

COMPANIES MENTIONED
Bristol-Myers Squibb, Daiichi Sankyo, Takeda Pharmaceutical Company, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

ページTOPに戻る

List of Tables/Graphs

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 JAPAN ORAL ANTICOAGULANTS MARKET ANALYSIS BY PRODUCT
FIGURE 3 JAPAN ORAL ANTICOAGULANTS MARKET ANALYSIS BY DISEASE INDICATION
FIGURE 4 JAPAN ORAL ANTICOAGULANTS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 5 KEY BUYING CRITERIA OF ORAL ANTICOAGULANTS MARKET
FIGURE 6 RESEARCH PROCESS OF MRFR
FIGURE 7 DRO ANALYSIS OF JAPAN ORAL ANTICOAGULANTS MARKET
FIGURE 8 DRIVERS IMPACT ANALYSIS: JAPAN ORAL ANTICOAGULANTS MARKET
FIGURE 9 RESTRAINTS IMPACT ANALYSIS: JAPAN ORAL ANTICOAGULANTS MARKET
FIGURE 10 SUPPLY / VALUE CHAIN: JAPAN ORAL ANTICOAGULANTS MARKET
FIGURE 11 JAPAN ORAL ANTICOAGULANTS MARKET, BY PRODUCT, 2024 (% SHARE)
FIGURE 12 JAPAN ORAL ANTICOAGULANTS MARKET, BY PRODUCT, 2024 TO 2035 (USD Million)
FIGURE 13 JAPAN ORAL ANTICOAGULANTS MARKET, BY DISEASE INDICATION, 2024 (% SHARE)
FIGURE 14 JAPAN ORAL ANTICOAGULANTS MARKET, BY DISEASE INDICATION, 2024 TO 2035 (USD Million)
FIGURE 15 JAPAN ORAL ANTICOAGULANTS MARKET, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
FIGURE 16 JAPAN ORAL ANTICOAGULANTS MARKET, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS

LIST OF TABLES
LIST OF ASSUMPTIONS
Japan ORAL ANTICOAGULANTS MARKET SIZE ESTIMATES; FORECAST
TABLE 1 BY PRODUCT, 2026-2035 (USD Million)
TABLE 2 BY PRODUCT, 2026-2035 (USD Million)
TABLE 3 BY DISEASE INDICATION, 2026-2035 (USD Million)
TABLE 4 BY DISEASE INDICATION, 2026-2035 (USD Million)
TABLE 5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
TABLE 6 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
ACQUISITION/PARTNERSHIP